Oncotarget

Research Papers:

The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies

Hengwei Fan, Wanwan Yi, Chenxing Wang and Jisheng Wang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:82643-82660. https://doi.org/10.18632/oncotarget.19740

Metrics: PDF 1891 views  |   HTML 1892 views  |   ?  


Abstract

Hengwei Fan1,*, Wanwan Yi2,*, Chenxing Wang1 and Jisheng Wang1

1Department of Hepatobiliary Surgery, The 2nd Affiliated Hospital & Yuying Children’s Hospital, Wenzhou Medical University, Zhejiang 325027, China

2Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University, Shanghai 200072, China

*These authors have contributed equally to this work

Correspondence to:

Jisheng Wang, email: [email protected]

Keywords: EMMPRIN, prognosis, clinicopathological significance, cancer, meta-analysis

Received: November 10, 2016     Accepted: June 20, 2017     Published: July 31, 2017

ABSTRACT

Extracellular matrix metalloproteinase inducer (EMMPRIN) has been reported to be associated with tumor formation and invasion in many studies. However, the clinicopathological significance and prognosis of EMMPRIN in cancer patients remains inconclusive. Therefore, we conducted a meta-analysis to assess the predictive potential of EMMPRIN in various cancers. By searching Pubmed, Cochrane library database and web of science comprehensively, 39studies with 5739 cases were included in our meta-analysis. The results indicated that EMMPRIN overexpression was significantly associated with poor outcome of cancers (HR=2.46, 95% CI: 2.21-2.75, P<0.0001). In addition, a significant relation was found between EMMPRIN overexpression and clinicopathological features, such as tumor stage (T3+T4/ T1+T2, OR=1.87, 95% CI:1.64-2.12, P<0.0001), tumor differentiation (poor/ well+ moderate, OR=1.09, 95% CI:1.60-2.23, P<0.0001), clinical stage (III+IV /I +II, OR=1.96, 95% CI:1.69-2.27, P<0.0001) and nodal metastasis (positive/negative, OR=2.37, 95% CI:1.93-2.90, P<0.0001). However, the expression of EMMRIN was not significantly associated with tumor stage in cervical cancer (OR=1.35, 95%CI: 0.73-2.48, P=0.33). In conclusion, EMMPRIN overxepression is significantly associated with clinicopathological characteristics and prognosis of cancers. Thus, EMMPRIN may be regarded as a promising bio-marker in predicting the clinical outcome of patients in cancers and could be used as the therapeutic target during clinical practices.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19740